Physician-scientists at IU School of Medicine conduct ground-breaking liver research to understand primary biliary cholangitis (PBC).

Primary Biliary Cholangitis

Primary biliary cholangitis (PBC), previously called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed.

Investigators

Craig Lammert, MD

Associate Professor of Medicine

Raj Vuppalanchi, M.D.

Professor of Medicine

Open Research Studies for Primary Biliary Cholangitis

Zydus PBC

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 26 weeks

Patient Population: Non-cirrhotic

Drug(s): Oral Saroglitazar

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects with Primary Biliary Cholangitis

Enrolling: Yes

Principle Investigator: Raj Vuppalanchi, MD

Duration: 59 weeks

Patient Population: Patients diagnosed with PBC

Drug(s): Saroglitazar Magnesium

Interested in this study? Please contact the clinical liver research team: iuliverr@iu.edu

View the study on clinicaltrials.gov

Closed Primary Biliary Cholangitis Studies

Intercept 302 - PBC

Enrolling: No
Principle Investigator: Raj Vuppalanchi, MD

Duration: Upwards 6 - 8 years.

Patient Population: PBC with total Bili > ULN and ≤3x ULN or ALP >5x ULN

Drug(s): Obeticholic Acid tablet or placebo
PBC Itch

Enrolling: No

Principle Investigator: Craig Lammert, MD

Duration: 1 visit

Patient Population: PBC/Pre-Transplant and history of no/minimal itch or severe itch.
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients with Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

Enrolling: No

Principle Investigator: Raj Vuppalanchi, MD

Duration: 21 weeks

Patient Population: Patients with moderate to severe itching.

Drug(s): Oral CR845

Clinicaltrials.gov